Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis
Expert Review of Pharmacoeconomics & Outcomes Research · 03.07.2025 · 25 (6) · 927-932
DOI: 10.1080/14737167.2025.2493728 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 15.04.2025. Verfasst von Francesco Ferrara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Asl Napoli 3 Sud, Nola, Naples, Italy. Hauptthemen laut MEDLINE: Hypercholesterolemia, Anticholesteremic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Elevated cholesterol levels are a significant contributor to cardiovascular disease risk. While statins have long been the cornerstone for lowering LDL cholesterol, their associated side effects have prompted the exploration of alternative treatments, including ezetimibe, bempedoic acid, PCSK9 inhibitors and inclisiran.f. RESEARCH DESIGN AND METHODS: This research seeks to analyze the usage patterns and financial implications during 2023 and 2024. The goal is to assess the economic impact of emerging therapies in hypercholesterolemia. RESULTS: Findings indicate a decline in the exclusive use of traditional statins and a rise in the adoption of newer and combination therapies. Statin monotherapy usage decreased markedly from 42% in 2023 to 30% in 2024. Combination treatments, such as statins paired with ezetimibe, remained steady at 17% across both time frames. The utilization of novel treatments, notably PCSK9 inhibitors, increased from 33% to 40% between the two periods, whereas bempedoic acid, whether used alone or with ezetimibe, stayed below 2%. CONCLUSION: The landscape of hypercholesterolemia treatment has expanded with several new therapeutic options. Bempedoic acid may mitigate adverse effects and enhance treatment efficacy, potentially delaying the need for costlier injectable medications like evolocumab, alirocumab, and inclisiran.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Asl Napoli 3 Sud, Nola, Naples, Italy.
- Ministry of Health, Rome, Italy.
- Italian Society of Hospital Pharmacy (SIFO), SIFO Secretariat of the Lombardy Region, Milan, Italy.
- Pharmaceutical Department, University of Naples Federico II, Napoli, Italy.
- Pharmaceutical department, Asl Salerno, Nocera Inferiore, Salerno, Italy.
- Pharmaceutical Department, Campania Regional Health System, Naples, Italy.
ORCID-Profile: Francesco Ferrara, Andrea Zovi
Zitieren
APA
Ferrara, F., Zovi, A., Langella, R., Panico, A., Scognamiglio, M., Trama, U., Nava, E., Capuozzo, M., Primiano, F., & Russo, G. (2025). Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis. Expert Review of Pharmacoeconomics & Outcomes Research, 25(6), 927-932. https://doi.org/10.1080/14737167.2025.2493728
Vancouver
Ferrara F, Zovi A, Langella R, Panico A, Scognamiglio M, Trama U, et al. Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2025;25(6):927-932. doi:10.1080/14737167.2025.2493728
BibTeX
@article{Ferrara2025,
author = {Ferrara, Francesco and Zovi, Andrea and Langella, Roberto and Panico, Angela and Scognamiglio, Manlio and Trama, Ugo and Nava, Eduardo and Capuozzo, Maurizio and Primiano, Ferdinando and Russo, Giuseppe},
title = {Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
volume = {25},
number = {6},
pages = {927--932},
doi = {10.1080/14737167.2025.2493728}
}
EUVIMED